Objectives Prior studies have shown that pathologic complete response at radical
cystectomy, a significant prognostic factor, can be attributed to both neoadjuvant …

Introduction There is controversy regarding the benefit of a grossly complete transurethral
resection of bladder tumor (TURBT) for muscle-invasive bladder cancer (MIBC) in patients …

Introduction Neoadjuvant chemotherapy (NAC) improves survival for patients undergoing
radical cystectomy for muscle-invasive bladder cancer (MIBC). The overall survival (OS) …

Background Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle invasive bladder
cancer improves all-cause and cancer specific survival. We aimed to evaluate whether the …

Purpose We estimated the proportion of patients who received neoadjuvant chemotherapy
for muscle-invasive bladder cancer whose tumors were downstaged by transurethral …

Purpose: To evaluate the potential oncologic benefit of a visibly complete transurethral
resection of a bladder tumor (TURBT) prior to neoadjuvant chemotherapy (NAC) and radical …

Objective This study aimed to comprehensively analyze the oncological long-term outcomes
of trimodal therapy (TMT) and radical cystectomy (RC) for the treatment of muscle-invasive …

Methods We retrospectively analyzed our TMT database for all patients treated between
2003 and 2017. Patients were treated with maximal transurethral resection of bladder tumor …

Background Delaying radical cystectomy (RC) after a diagnosis of muscle-invasive bladder
cancer (MIBC) has been associated with adverse survival. However, data are lacking …

Purpose: While the presence of residual disease at the time of radical cystectomy for bladder
cancer is an established prognostic indicator, controversy remains regarding the importance …